• Company
• Lutathera’s partner ‘LysaKare’ may be prescribed at GHs
• by Eo, Yun-Ho Apr 11, 2022 05:58am

• Policy
• The adverse drug reaction rate of Trulicity is 19%
• by Lee, Hye-Kyung Apr 11, 2022 05:58am

• Policy
• NHIS to study measures on improving the PVA system
• by Lee, Tak-Sun Apr 11, 2022 05:58am

• Policy
• National Responsibility for the Side Effects of Vaccines
• by Lee, Jeong-Hwan Apr 11, 2022 05:58am

• Company
• HK inno.N's K-CAB has ended Phase 1 in US
• by Kim, Jin-Gu Apr 11, 2022 05:58am

• Policy
• CAR T-cell therapy has shown the disappearance of leukemia
• by Kim, Jung-Ju Apr 11, 2022 05:57am

• Policy
• Chinese companies are set to debut in the domestic market
• by Lee, Tak-Sun Apr 11, 2022 05:57am

• Company
• Rising COVID-19 cases impede progress of bioequivalence test
• by Chon, Seung-Hyun Apr 8, 2022 06:08am

• Policy
• The benefit adequacy of Lorviqua was recognized
• by Lee, Tak-Sun Apr 8, 2022 06:08am

• Company
• GC Pharma’s Hunterase ICV approved for P1T in Korea
• by Kim, Jin-Gu Apr 8, 2022 06:08am